(VIANEWS) – Shares of ABIONYX PHARMA (CAC 40: ABNX.PA) dropped by a staggering 22.74% to €1.40 at 11:37 EST on Wednesday, after two successive sessions in a row of gains. CAC 40 is dropping 1.61% to €7,259.73, after two sequential sessions in a row of losses. This seems, as yet, an all-around bearish trend trading session today.
ABIONYX PHARMA’s last close was €1.81, 30.71% under its 52-week high of €2.62.
About ABIONYX PHARMA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.
Earnings Per Share
As for profitability, ABIONYX PHARMA has a trailing twelve months EPS of €-0.15.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -91.7%.
Yearly Top and Bottom Value
ABIONYX PHARMA’s stock is valued at €1.40 at 11:37 EST, way below its 52-week high of €2.62 and above its 52-week low of €1.39.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ABIONYX PHARMA’s stock is considered to be oversold (<=20).
Revenue Growth
Year-on-year quarterly revenue growth grew by 9640.7%, now sitting on 3.28M for the twelve trailing months.
More news about ABIONYX PHARMA (ABNX.PA).
